Spondyloarthritis & psoriatic arthritis
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
Authors' conclusion
At 3 years, improvements in PROs following ustekinumab or TNFi treatment were generally comparable; however, TNFi-treated patients achieved a greater improvement in work productivity, although this group started from a lower baseline. Achievement of effectiveness endpoints, independent of treatment group, also improved PROs.
Study context
- Population
- Patients with psoriatic arthritis (PsA) prescribed first- to third-line ustekinumab or a tumour necrosis factor inhibitor (TNFi) and remaining on that drug for 3 years (mean age 49.1 years, 47.8% female)
- Participants
- 437 patients
- Exposure
- Ustekinumab vs TNFi
- Outcome
- Change from baseline in PROs (EQ-5D VAS, PsAID-12, WPAI)
- Follow-up
- 3 years
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Ustekinumab
11.0
mean · 95% CI 6.5–15.4
TNFi
18.9
mean · 95% CI 14.0–23.9
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Ustekinumab | TNFi |
|---|---|---|
| PsAID-12 (range 0-10), mean change from baseline · 3 years | −2.9 (95% CI −3.2–-2.5) | −3.5 (95% CI −3.9–-3.2) |
| Work productivity reduction due to PsA (WPAI), mean, at baseline | 43.3 (95% CI 35.6–51.1) | 58.8 (95% CI 52.4–65.2) |
| Work productivity (WPAI), mean improvement · 3 years | 24.9% (95% CI 15.8–34.0) | 44.5% (95% CI 38.4–50.6) |
Work productivity (WPAI), mean improvement · 3 years
- Greater improvement with TNFi; work productivity ultimately comparable between groups
- Similar trend in activity impairment
Patient-reported outcomes (PROs) and WPAI by achievement of cDAPSA low disease activity (LDA)/remission, minimal disease activity (MDA) and very low disease activity (VLDA)
- Patients in both groups achieving effectiveness endpoints had greater improvement in PROs and WPAI than those not achieving them
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →